Drug intelligence / Profile preview

DNX-6000

Development stage: Preclinical
Lead developer: Dynamix Pharmaceuticals
Modality: Small Molecules

Overview

DNX-6000 is a preclinical-stage small molecule therapeutic being developed by Dynamix Pharmaceuticals (DynamX). It is designed to target cancer metabolism, a field focused on the unique biochemical pathways that tumor cells utilize for growth and survival. As of the current pipeline information, the specific molecular target of DNX-6000 remains undisclosed. The program is currently in the lead optimization phase, aiming to identify a candidate for further development in oncology.

Other names: DNX-6000DNX6000DNX 6000

Beyond the preview

Go deeper on DNX-6000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNX-6000.

Explore the full profile